Essity AB header image

Essity AB

ESSITY A

Equity

ISIN SE0009922156 / Valor 36846754

NASDAQ Nordic Exchange Stockholm, Equities (2026-11-06)
SEK 288.00-1.03%

Essity AB
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Essity AB is a leading global hygiene and health company operating through three main segments: Professional Hygiene, Health & Medical, and Consumer Goods. In the Professional Hygiene division, Essity delivers sustainable hygiene management solutions, including dispensing systems for tissues, soaps, and sanitizers, alongside wiping and cleaning products tailored for businesses and public spaces. The Health & Medical segment provides essential products and services such as incontinence care, wound care, compression therapy, and orthopedics, supporting patients, caregivers, and healthcare professionals throughout the continuum of care. Additionally, the Consumer Goods division offers personal and home hygiene products, including baby care, feminine care, incontinence care, and consumer tissue products, addressing the needs of consumers at all life stages. This diversified portfolio enables Essity to maintain a significant presence in both professional and consumer markets, promoting clean and healthy environments worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (06.11.2026):

Essity AB — Interim results for Quarter 2, 2026: net sales SEK 35,061m (+2.6%), organic sales growth 0.3% (volume +1.4%, price/mix -1.1%). EBITA SEK 4,105m and EBITA excl. IAC SEK 4,685m (EBITA margin excl. IAC 13.4%, down 0.3 ppt). Profit for the period SEK 2,693m; earnings per share SEK 3.94. Operating cash flow for Q2 was SEK 2,790m (H1 operating cash flow SEK 7,144m). A SEK 3bn share buyback program was launched (May 12, 2026) and SEK 554m was repurchased in the period. Net debt at June 30, 2026 was SEK 28,462m and net debt/EBITDA excl. IAC was 1.11.

Sales and organic growth

Net sales rose 2.6% to SEK 35,061m. Organic growth was modest at 0.3, driven by higher volumes in Health & Medical, Personal Care and Professional Hygiene; price/mix was a -1.1% headwind. The acquisition of a North American feminine‑care business added ~1.7% to sales. Consumer Tissue saw a notable organic decline (-5.3%).

Profitability and margins

EBITA amounted to SEK 4,105m; EBITA excl. IAC was SEK 4,685m (IAC of SEK -580m mainly related to the cost‑savings program). EBITA margin excl. IAC fell to 13.4% from 13.7%. Gross profit margin was 32.6% (down 0.7 ppt) with higher costs for distribution and energy partly offset by savings in COGS (~SEK 160m).

Cash flow and shareholder returns

Operating cash flow for Q2 was SEK 2,790m (H1: SEK 7,144m). The company paid the ordinary dividend (SEK 5,956m in the period) and initiated the SEK 3bn buyback program; SEK 554m of buybacks executed between May 12 and June 30. These outflows contributed to negative net cash flow for the period.

Balance sheet and leverage

Net debt totaled SEK 28,462m at June 30, 2026 (up SEK 1,919m vs Dec 31, 2025). Interest‑bearing gross debt was SEK 38,547m and average debt maturity 2.8 years. Key returns: ROCE 14.0% (ROCE excl. IAC 16.0%). Net debt/EBITDA excl. IAC stood at 1.11.

Business‑area highlights

- Health & Medical: net sales SEK 6,918m, organic +3.1%; EBITA excl. IAC SEK 1,310m and margin 18.9%. - Personal Care: net sales SEK 8,815m (+14% reported; organic +3.8%); EBITA excl. IAC SEK 1,131m (margin 12.8%). Acquisition in North America supported sales but weighed on margin in transition. - Consumer Tissue: net sales SEK 10,202m (-4% reported; organic -5.3%); EBITA excl. IAC SEK 988m (margin 9.7%), hit by lower volumes and prior price reductions. Strategic review of this business area was initiated. - Professional Hygiene: net sales SEK 9,127m (+1%; organic +2.1%); EBITA excl. IAC SEK 1,573m (margin 17.2%), with continued premium product growth.

Other items and near‑term outlook

Essity flagged continued external volatility and cost inflation (transportation, input costs). Management expects positive effects in H2 from the new organizational structure, efficiency improvements and selective price increases. Ongoing cost‑savings programs (IAC impact) and the strategic review of Consumer Tissue are key near‑term focuses.

Summarized from source with an LLMView Source

Key figures

9.30%1Y
14.5%3Y
1.59%5Y

Performance

19.6%1Y
19.3%3Y
22.1%5Y

Volatility

Market cap

1571 M

Market cap (USD)

Daily traded volume (Shares)

11,237

Daily traded volume (Shares)

1 day high/low

297 / 293.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20